コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ts of large, therapeutic proteins, such as a monoclonal antibody.
2 re abolished by pre-treatment with the GFRAL monoclonal antibody.
3 and of a much smaller fluorescently labeled monoclonal antibody.
4 , a fully human IgG1 anti-yellow fever virus monoclonal antibody.
5 in complex with a broadly neutralizing human monoclonal antibody.
6 able of neutralizing virus when expressed as monoclonal antibodies.
7 hibit markedly higher thermal stability than monoclonal antibodies.
8 variants with affinities that rival those of monoclonal antibodies.
9 cterized using a panel of intertype-reactive monoclonal antibodies.
10 rapidly identify and characterize protective monoclonal antibodies.
11 nding site for several previously identified monoclonal antibodies.
12 and to developing vaccines, antivirals, and monoclonal antibodies.
13 ssays that tracked 170 APOL1 domain-specific monoclonal antibodies.
14 (KD range: 0.399-233 nM) of CD160 targeting monoclonal antibodies.
15 nel of novel APOL1-specific mouse and rabbit monoclonal antibodies.
16 the potency of convalescent plasma or human monoclonal antibodies.
17 development of targeted therapeutics such as monoclonal antibodies.
18 HIV-1 particles to immobilized Env-specific monoclonal antibodies.
19 rovide an initial screen for all therapeutic monoclonal antibodies.
20 itope affinity for two groups of widely used monoclonal antibodies.
21 ability samples, and trisulfide standards of monoclonal antibodies.
22 apsids to impact recognition by neutralizing monoclonal antibodies.
23 ort had induction therapy with polyclonal or monoclonal antibodies, 28% did not receive calcineurin i
24 structure of the broadly neutralizing human monoclonal antibody 3G12 bound to the RSV G central cons
25 Here we report a therapeutic antagonistic monoclonal antibody, 3P10, that targets GFRAL and inhibi
26 d characterization of such MAbs revealed one monoclonal antibody, 53C10, exhibiting a potent neutrali
27 cytopenia using the rat anti-mouse GPIbalpha monoclonal antibody 5A7, generated in our laboratory.
32 tological analysis showed some uptake of the monoclonal antibody after IA delivery, and OBBBO signifi
33 overy of clinically applicable high affinity monoclonal antibodies against a broad range of targets.
34 map the fine structure of the epitopes of 28 monoclonal antibodies against amyloid-beta using immunos
35 ting the pairwise combination of 11 parental monoclonal antibodies against CD73 was generated by Fab-
39 e investigated two fully human, neutralizing monoclonal antibodies against severe acute respiratory s
40 therapy with plasma from recovered patients, monoclonal antibodies against the viral S-protein, and s
41 us and intravenous evinacumab, a fully human monoclonal antibody against angiopoietin-like 3, are not
46 were treated with spartalizumab, a humanized monoclonal antibody against the programmed death-1 (PD-1
47 s in CMV immune monitoring, vaccination, and monoclonal antibodies, all of which have the potential t
48 tralization by receptor-binding domain (RBD) monoclonal antibodies and convalescent sera from people
49 sted several published SARS-CoV RBD-specific monoclonal antibodies and found that they do not have ap
51 mon serious toxicity after administration of monoclonal antibodies and immune effector cell therapies
52 the ability to target B cells with anti-CD20 monoclonal antibodies and plasma cells with proteasome i
53 d cell adhesive properties of CD31, specific monoclonal antibodies and recombinant proteins were rega
54 the elution behavior of various therapeutic monoclonal antibodies and their fragments (25-150 kDa) h
55 molecular interactions between a protective monoclonal antibody and a MenA capsular polysaccharide f
56 ed the protective efficacy of a neutralizing monoclonal antibody and found that pretreatment, even in
57 in the N-glycan profile of a biotherapeutic monoclonal antibody and was able to achieve sensitive gl
58 on-line system was versatile, only different monoclonal antibodies, anti-apolipoprotein B-100, anti-C
60 igns of affinity maturation, gut-derived IgA monoclonal antibodies are cross-reactive in the sense th
66 ate this approach, we show that binders to a monoclonal antibody are identified in proportion to libr
68 Most newly developed biologics, including monoclonal antibodies, are structurally complex and are
70 Using a plasmid encoding an anti-poxvirus monoclonal antibody (as a reporter of protein expression
72 y human, CD40 pathway blocking, nondepleting monoclonal antibody being developed as an immunosuppress
74 d was further confirmed by analyzing another monoclonal antibody, bevacizumab, as well as a soluble a
75 sed the efficacy and safety of the antitoxin monoclonal antibodies bezlotoxumab and actoxumab in part
79 ecently, numerous broadly neutralizing HIV-1 monoclonal antibodies (bNAbs) have been developed that p
82 1 (subfamily B), bound protective anti-FHbp monoclonal antibodies, bound high levels of human FH, an
83 , which was blocked completely by an anti-C5 monoclonal antibody, but not by a factor D inhibitor, in
84 rization of typhoid toxin-neutralizing human monoclonal antibodies by immunizing genetically engineer
85 lengths and tested them with polyclonal and monoclonal antibodies by inhibition enzyme-linked immuno
86 ral and functional studies, we show that the monoclonal antibodies can be clustered into classes that
87 deployed, the rapidity with which antiviral monoclonal antibodies can be isolated and engineered off
88 at might limit the therapeutic usefulness of monoclonal antibodies can be mitigated by the use of ant
91 inase inhibitor (TKI) afatinib plus the EGFR monoclonal antibody cetuximab was previously shown to ov
93 nd structural basis as to how two anti-CHIKV monoclonal antibodies, CHK-124 and CHK-263, potently inh
94 gest a clinically relevant impact of IVIg on monoclonal antibody clearance and indirectly hint at an
96 mbination with a suboptimal dose of anti-CD3 monoclonal antibody (combined therapy [CT], 1 x 5 mug [C
98 covery and development of virus-neutralizing monoclonal antibodies could be one approach to treat or
100 ently tested with samples of anti-SARS-CoV-2 monoclonal antibody CR3022 (0.1 mug/ml, 1.0 mug/ml, 10 m
102 al virus (RSV), and several RSV vaccines and monoclonal antibodies currently in clinical trials, unde
105 otherapies such as the use of vaccination or monoclonal antibodies directed against aggregated, toxic
110 an approach utilizing synthetic DNA-encoded monoclonal antibodies (dmAbs) for direct in vivo product
111 , routinely used for the characterization of monoclonal antibodies (enzyme-linked immunosorbent assay
113 tested using placebo group data from MODIFY (Monoclonal Antibodies for C. difficile Therapy) I and II
114 rt that Fc engineering of anti-influenza IgG monoclonal antibodies for selective binding to the activ
115 B cell membrane protein that is targeted by monoclonal antibodies for the treatment of malignancies
116 characterize a panel of plasmablast-derived monoclonal antibodies from an infected child whose antib
117 The isolation and properties of neutralizing monoclonal antibodies from COVID-19 patients provide add
118 olation of sixty-one SARS-CoV-2-neutralizing monoclonal antibodies from five patients infected with S
119 tients treated with atezolizumab (anti-PD-L1 monoclonal antibody) from multiple randomized trials rep
120 omplement-targeted immunotherapies including monoclonal antibodies, fusion proteins and peptidomimeti
121 is, while its pharmaceutical inhibition by a monoclonal antibody has been approved for the treatment
123 ab, a high-affinity interleukin-17A (IL-17A) monoclonal antibody, has previously shown efficacy in ra
125 sed interest in malaria elimination, TBV and monoclonal antibodies have moved to the center stage of
126 mpleted and the first drugs, all therapeutic monoclonal antibodies, have been approved for the treatm
127 haracterized for binding to a panel of human monoclonal antibodies (HMAbs) and the coreceptor CD81 to
128 EV) were successfully treated with anti-VEEV monoclonal antibody Hu1A3B-7 delivered in glucosamine-co
132 e regression, Tregs were depleted using CD25 monoclonal antibody in atherosclerotic mice during apoli
133 argetuximab plus pembrolizumab (an anti-PD-1 monoclonal antibody) in previously treated patients with
134 nd antigenicity analysis with a panel of six monoclonal antibodies, including antibodies that recogni
135 is end, we integrated the well-characterized monoclonal antibody into an electrochemical biosensor an
138 lls with proteasome inhibitors and anti-CD38 monoclonal antibodies, it is increasingly important to d
145 trode interface promotes the localization of monoclonal antibodies (mAb) selective for binding the ep
146 ch harness the high targeting specificity of monoclonal antibodies (mAb) with the potency of small mo
149 tigen of T. marneffei using a yeast-specific monoclonal antibody (MAb) 4D1 during phase transition.
151 ying the composition of protective antiviral monoclonal antibody (mAb) cocktails are poorly defined.
153 ber can reduce the abundance of low-affinity monoclonal antibody (mAb) epitopes while retaining high-
156 ut of this assay to the discovery of a novel monoclonal antibody (mAb) sandwich pair for the detectio
157 uate the potential of SEC-CIU to distinguish monoclonal antibody (mAb) subclasses, illustrating the e
158 rated anti-bacterial efficacy of a humanised monoclonal antibody (mAb) targeting the O25b O-antigen o
161 ciated with the discovery and development of monoclonal antibody (mAb) therapeutics is the determinat
162 ent forms, it is important to use a specific monoclonal antibody (mAb) to characterize these molecule
164 es with a cross-reactive, neutralizing human monoclonal antibody (mAb), m102.4, targeting the G glyco
166 is study, we investigated how a neutralizing monoclonal antibody (MAb), which targets the receptor-bi
168 the typical form of gI, as a previously used monoclonal antibody mAb3104 and a newly made peptide ant
170 ture of native bovine IRBP in complex with a monoclonal antibody (mAb5) by cryo-electron microscopy,
171 ted in vitro two Frd7 blocking strategies: a monoclonal antibody (mAbFzd7) against Fzd7 and a soluble
172 e report the first naturally occurring human monoclonal antibodies (mAbs) against HeV receptor bindin
174 ne hybridoma technology to generate 25 mouse monoclonal antibodies (MAbs) against the GPC of MACV.
175 covery platform to isolate hundreds of human monoclonal antibodies (mAbs) against the SARS-CoV-2 spik
176 , common components of storage solutions for monoclonal antibodies (mAbs) and ADCs, such as nonvolati
177 the current FDA and EMA approved therapeutic monoclonal antibodies (mAbs) are based on humanized or h
178 d intranasal gepants and the injectable CGRP monoclonal antibodies (mAbs) are described, as are recen
182 or hemophilia therapy, 2 types of inhibitory monoclonal antibodies (mAbs) are tested: A type I active
186 post-translational modifications [PTMs]) of monoclonal antibodies (mAbs) during drug development.
188 HIV-1 Env constant region 1 and 2 (C1C2) monoclonal antibodies (MAbs) frequently mediate potent a
190 We previously isolated a large panel of monoclonal antibodies (mAbs) from B cells of a human sur
191 ecific, hemagglutination inhibition-inactive monoclonal antibodies (MAbs) from elderly individuals.
193 lational modifications (PTMs) in therapeutic monoclonal antibodies (mAbs) is essential during their p
195 ericidal activity induced by combinations of monoclonal antibodies (mAbs) raised against factor H-bin
196 enic HPV genotypes by using a large panel of monoclonal antibodies (MAbs) raised against the L1 prote
197 ntial for rapid advancement into the clinic, monoclonal antibodies (mAbs) represent a highly promisin
200 n undetermined, in part because of a lack of monoclonal antibodies (mAbs) that can distinguish these
201 Here, we isolated and characterized human monoclonal antibodies (mAbs) that target IBV NA from an
202 We aimed to characterize eight anti-PSA monoclonal antibodies (mAbs) to assess the prostate canc
203 zed, non-Fcgamma receptor (FcgammaR)-binding monoclonal antibodies (mAbs) to CD3 have antileukemic pr
204 tibody responses, we produced 28 antiadhesin monoclonal antibodies (MAbs) to representative adhesins
205 re used for the generation of nonimmunogenic monoclonal antibodies (MAbs), and characterization of su
214 tivity of both convalescent plasma and human monoclonal antibodies measured using each virus correlat
215 have been used to add and remove fucose from monoclonal antibody N-glycans, with significant impacts
216 e identify three CVA16-specific neutralizing monoclonal antibodies (nAbs) with therapeutic potential:
217 his methodology to the study of HCPs in NIST monoclonal antibody (NISTmAb), more than 150 HCPs were c
218 the anti-programmed cell death-1 (anti-PD-1) monoclonal antibody nivolumab, has shown efficacy in tum
219 re mapped using milk-specific human sera and monoclonal antibodies on overlapping and recombinant pep
220 toneal injection of anti-SQSTM1-neutralizing monoclonal antibodies or conditional depletion of Insr i
221 N-terminal domain that confer resistance to monoclonal antibodies or convalescent plasma can be read
222 logies, which can be attenuated by anti-ApoE monoclonal antibody or deletion of ApoE via its specific
223 T) or mutant human INSR Two murine anti-INSR monoclonal antibodies, previously shown to be surrogate
224 imaging the binding of a protease-activated monoclonal antibody prodrug, called a Probody((R)) thera
225 st-translational modification of therapeutic monoclonal antibodies produced in mammalian cells and is
226 EVD demonstrated survival benefits from two monoclonal antibody products targeting the EBOV membrane
228 largest class of biotherapeutics, with five monoclonal antibodies ranked in the top 10 blockbuster d
232 ockade of TNF, IL-6, or IL-10R function with monoclonal antibodies reduced lung pathology and provide
237 depends on a TspanC8 partner, and a lack of monoclonal antibodies specific for most TspanC8s has hin
238 ID-19-convalescent patients and neutralizing monoclonal antibodies specific to SARS-CoV-2 antigens ca
240 systematically evaluated using an anti-CD22 monoclonal antibody spiked into monkey and human serum,
241 r not with GluN1) and a human NMDAR-specific monoclonal antibody (SSM5) derived from plasma cells of
242 x in vitro against invasion inhibitory human monoclonal antibodies targeting a conserved binding doma
243 out to be particularly evident, a number of monoclonal antibodies targeting IL-17 pathways have been
244 Immune checkpoint inhibitors (ICIs) are monoclonal antibodies targeting immune checkpoint molecu
245 designed an immunogen to generate the first monoclonal antibodies targeting Tspan15, a model TspanC8
248 nd efficacy of belimumab, a fully human IgG1 monoclonal antibody targeting the cytokine B cell-activa
252 d pharmacodynamics (PD) of the human anti-C5 monoclonal antibody tesidolumab (LFG316) in end-stage re
253 -independent neutralization by a panel of gB monoclonal antibodies than a wild-type gC rescuant virus
256 Here we develop mouse and human anti-NS1 monoclonal antibodies that protect against ZIKV in both
261 fants of 1 or 2 doses of suptavumab, a human monoclonal antibody that can bind and block a conserved
262 208) is an Fc-enhanced, humanised, anti-CD19 monoclonal antibody that has shown preclinical and singl
269 lind, Phase II placebo-controlled trial of a monoclonal antibody that targets the HA stalk (CR6261) i
277 mmunosuppressive tumor microenvironment with monoclonal antibodies to enhance NK cell activation and
278 or-specific CD8 T cells, and with anticancer monoclonal antibodies to increase ADCC and antitumor eff
280 A) is based on the principle that binding of monoclonal antibodies to specific epitopes of T. b.
282 hase 1-2 study of nivolumab, a PD-1 blocking monoclonal antibody, to determine its safety, pharmacoki
290 fter four days, up to 30 ng/mL of functional monoclonal antibody were detected in the serum of rabbit
291 lls, we generated several HPV-specific human monoclonal antibodies, which exhibited a high degree of
292 s, it is currently solely based on expensive monoclonal antibodies, which often inflict immune-relate
293 e of Notch1 short interference RNA or Notch1 monoclonal antibodies, which produce a more specific blo
294 on and predominantly encoded strain-specific monoclonal antibodies, which suggests a naive B cell ori
295 n combination with an anti-GD2 or anti-4-1BB monoclonal antibody, which resulted in increase in survi
298 tory or intolerant (or both) to an anti-CD38 monoclonal antibody with an Eastern Cooperative Oncology